Intapp Posts Better-Than-Expected Earnings, Joins Sapiens International, Arcturus Therapeutics, Gildan Activewear And Other Big Stocks Moving Higher On Wednesday - Agilon Health ( NYSE:AGL ) , Arcturus Therapeutics ( NASDAQ:ARCT )
U.S. stocks were higher, with the Dow Jones index gaining around 250 points on Wednesday. Shares of Intapp, Inc. INTA rose sharply during Wednesday's session after the company reported better-than-expected fourth-quarter financial results.
Mercury Systems Posts Better-Than-Expected Earnings, Joins Green Dot, Arcturus Therapeutics And Other Big Stocks Moving Higher On Tuesday - AAON ( NASDAQ:AAON ) , American Airlines Group ( NASDAQ:AAL )
U.S. stocks were higher, with the Dow Jones index gaining around 500 points on Tuesday. Shares of Mercury Systems, Inc. MRCY rose sharply during Tuesday's session after the company reported better-than-expected Q4 financial results.
Arcturus Therapeutics ( ARCT ) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of +69.37% and +20.84%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Clearside Biomedical, Inc. ( CLSD ) Reports Q2 Loss, Beats Revenue Estimates
Clearside Biomedical (CLSD) delivered earnings and revenue surprises of +50.00% and +87.07%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Insmed ( INSM ) Reports Q2 Loss, Beats Revenue Estimates
Insmed (INSM) delivered earnings and revenue surprises of -30.77% and +3.87%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Tango Therapeutics, Inc. ( TNGX ) Reports Q2 Loss, Lags Revenue Estimates
Tango Therapeutics (TNGX) delivered earnings and revenue surprises of 0.00% and -48.58%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Wall Street Analysts Think Arcturus Therapeutics ( ARCT ) Could Surge 371.35%: Read This Before Placing a Bet
The mean of analysts' price targets for Arcturus Therapeutics (ARCT) points to a 371.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Wall Street Analysts Believe Arcturus Therapeutics ( ARCT ) Could Rally 503.6%: Here's is How to Trade
The consensus price target hints at a 503.6% upside potential for Arcturus Therapeutics (ARCT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Arcturus Therapeutics ( ARCT ) Reports Q1 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 67.09% and 3.10%, respectively, for the quarter ended March 2025. Do the numbers hold clues to what lies ahead for the stock?
ADAR1 Capital Management Issues Open Letter to Keros Therapeutics Stockholders - Keros Therapeutics ( NASDAQ:KROS )
Announces Intention to Withhold Votes for Directors Dr. Mary Ann Gray and Dr. Alpna Seth
Cathie Wood Strengthens AI Chip Holdings With Nvidia And AMD Purchases, Reduces Palantir Position By Another $38.8 Million - ARK Fintech Innovation ETF ( BATS:ARKF ) , Advanced Micro Devices ( NASDAQ:AMD )
On Wednesday, Cathie Wood's Ark Invest made notable trades involving Nvidia Corp. NVDA, Advanced Micro Devices Inc. AMD, Palantir Technologies Inc. PLTR, and Tempus AI Inc. TEM. These trades reflect Ark's ongoing strategy to adjust its portfolio in response to market dynamics and company ...
Earnings Preview: Arcturus Therapeutics ( ARCT ) Q1 Earnings Expected to Decline
Arcturus Therapeutics (ARCT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Arcturus Gets FDA's Fast Track Tag for Influenza Vaccine Candidate
The FDA bestows a Fast Track designation to ARCT's sa-mRNA vaccine candidate, ARCT-2304, for active immunization to prevent pandemic influenza A virus H5N1.
RNA Therapeutics Market is expected to generate a revenue of USD 22.37 Billion by 2032, Globally, at 9.4% CAGR: Verified Market Research®
Lewes, Delaware, March 17, 2025 ( GLOBE NEWSWIRE ) -- The Global RNA Therapeutics Market Size is projected to grow at a CAGR of 9.4% from 2026 to 2032, according to a new report published by Verified Market Research®.
Arcturus Therapeutics ( ARCT ) Reports Q4 Loss, Misses Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of -226.47% and 60.60%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Axsome ( AXSM ) Surges 20.2%: Is This an Indication of Further Gains?
Axsome (AXSM) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Arcturus Therapeutics ( ARCT ) Reports Q3 Loss, Lags Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 62.86% and 15.23%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Arcturus Gears Up to Report Q3 Earnings: Here's What to Expect
On ARCT's third-quarter 2024 earnings call, investors' focus is likely to be on the upcoming launch of its COVID-19 vaccine, Kostaive and other pipeline updates.
Arcturus Therapeutics ( ARCT ) Upgraded to Buy: What Does It Mean for the Stock?
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
ARCT Stock Up as Updated COVID-19 Jab Betters PFE & BNTX's Comirnaty
Arcturus stock gains as the company reports that its sa-mRNA COVID-19 vaccine, ARCT-154, shows superior efficacy compared with treatment with Comirnaty.
Arcturus Therapeutics/CSL Partnered COVID-19 Vaccine Surpasses Pfizer's Comirnaty Shot, Even At Lower Doses - Arcturus Therapeutics ( NASDAQ:ARCT ) , Pfizer ( NYSE:PFE ) , CSL ( OTC:CSLLY )
CSL Limited CSLLY and Arcturus Therapeutics ARCT announced the results of a Phase 3 head-to-head study of ARCT-154, a self-amplifying ( sa-mRNA ) COVID-19 vaccine, compared to Pfizer Inc's PFE shot Comirnaty.
Here's Why Investors Should Invest in Arcturus Stock Now
Here, we are discussing some reasons why investing in ARCT stock now may turn out to be a prudent move.
CSL And Arcturus Announce Japanese Approval For Updated Self-amplifying MRNA COVID-19 Vaccine
( RTTNews ) - Australian biotechnology company CSL Ltd. ( CSL.AX, CSLLY.PK ) and sa-mRNA pioneer Arcturus Therapeutics ( ARCT ) , announced Friday that Japan's Ministry of Health, Labor and Welfare ( MHLWs ) granted approval and authorization for their updated self-amplifying mRNA ( sa-mRNA ) ...
New Strong Buy Stocks for September 13th
ARCT, MHO, FMBH, PAM and ANGO have been added to the Zacks Rank #1 (Strong Buy) List on September 13, 2024.
BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
BMRN divulges ambitious plans for business growth over the next 10 years. It expects yearly sales to grow at a mid-teen rate through 2034.
Does Arcturus Therapeutics Have the Potential to Rally 216.35% as Wall Street Analysts Expect? - Arcturus Therapeutics ( NASDAQ:ARCT )
Arcturus Therapeutics ARCT closed the last trading session at $21.10, gaining 2.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $66.75 indicates a 216.4% upside ...
Does Arcturus Therapeutics ( ARCT ) Have the Potential to Rally 216.35% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 216.4% in Arcturus Therapeutics (ARCT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the ...
SNY's MS Drug Meets Goal in One Phase III Study; Misses in Two Others
Sanofi's HERCULES phase III study on tolebrutinib meets primary endpoint, showing an improvement in delaying time to onset of confirmed disability progression.
Rhythm Stock Up as FDA Accepts Obesity Drug sNDA for Younger Kids
RYTM gains 8% as FDA accepts Imcivree sNDA seeking label expansion of the drug to treat obesity in kids as young as two years old.
AstraZeneca ( AZN ) Denies Rumors About UK Facility Relocation
Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.
Sutro Biopharma ( STRO ) Rises 9% in the Past Week: Here's Why
Sutro Biopharma (STRO) gains 9% in a week after initiating a phase II study on its lead candidate, luvelta, to treat FRa-expressing lung cancer.
Here's Why You Should Consider Buying Akebia ( AKBA ) Stock
Here, we discuss some reasons why buying Akebia (AKBA) stock now may turn out to be a prudent move.
J&J ( JNJ ) Gets EU Approval for Bladder Cancer Drug Balversa
The approval of J&J's (JNJ) Balversa (erdafitinib) for treating unresectable or metastatic urothelial carcinoma is based on data from the phase III THOR study.
What Makes Arcturus Therapeutics ( ARCT ) a New Strong Buy Stock
Arcturus Therapeutics (ARCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Galapagos ( GLPG ) Up on FDA Nod to Begin Phase I/II Lymphoma Study
Galapagos (GLPG) rises in pre-market hours on Aug 23, after the FDA nod to begin early to mid-stage study of GLPG5101 for non-Hodgkin lymphoma patients.
New Strong Buy Stocks for August 23rd
RHHBY, SBSI, FCCO, APELY and ARCT have been added to the Zacks Rank #1 (Strong Buy) List on August 23, 2024.
Bristol Myers' HCC Combo Drug Accepted for FDA Review - Bristol-Myers Squibb ( NYSE:BMY )
Bristol Myers BMY announced that the FDA has accepted its supplemental Biologics License Application ( sBLA ) for the immunotherapy drug, Opdivo ( nivolumab ) , in combination with Yervoy ( ipilimumab ) .
Why Grifols ( GRFS ) Stock Price Moved Up 7% on Wednesday
A Bloomberg article suggests that Brookfield Asset Management is in discussions with banks to raise nearly $11 billion to fund the takeover of Spain-based Grifols (GRFS).
Bristol Myers' ( BMY ) HCC Combo Drug Accepted for FDA Review
Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
Dr. Reddy's ( RDY ) , Kainomyx Sign Potential Deal for Malaria Drug
Dr. Reddy's (RDY) is gearing up to potentially collaborate with Kainomyx to jointly develop an affordable anti-malarial drug.
Xenon ( XENE ) Focuses on Neuro Candidate Amid Pipeline Woe
Xenon's (XENE) clinical studies of azetukalner in epilepsy and other neurological disorders are progressing well. However, any setback is set to hurt the stock in the absence of a deep pipeline.
J&J ( JNJ ) Gets FDA Nod for Chemotherapy-Free Lung Cancer Therapy
The approval is based on late-stage study data wherein treatment with J&J's (JNJ) Rybrevant plus Lazcluze cut the risk of disease progression or death by 30% in certain NSCLC patients.
Liquidia ( LQDA ) Down on FDA Delaying Full Approval for Yutrepia
The FDA grants tentative approval to Liquidia's (LQDA) inhaled powder for two lung disorder indications. Full approval may be granted after May 2025, when the regulatory exclusivity of a competing product expires.
AbbVie ( ABBV ) Gets Nod in EU for Lymphoma Drug's Expanded Use
AbbVie's (ABBV) Tepkinly gets conditional approval in the EU to treat third-line patients with relapsed or refractory follicular lymphoma as a second indication.
AN2 Therapeutics Plunges 66% in a Month: Here's Why - Arcturus Therapeutics ( NASDAQ:ARCT ) , AN2 Therapeutics ( NASDAQ:ANTX )
AN2 Therapeutics ANTX, a clinical-stage company, leverages its boron chemistry platform to develop novel small molecule therapeutics to potentially treat various infectious diseases and cancer indications.
AN2 Therapeutics ( ANTX ) Plunges 66% in a Month: Here's Why
AN2 Therapeutics (ANTX) falls 66% in a month after terminating its mycobacterium avium complex lung disease study of epetraborole due to unsatisfactory efficacy results.
FDA Expands AstraZeneca's ( AZN ) Imfinzi Label in Lung Cancer
This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.
Achilles Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Updates
- Announced research collaboration with Arcturus Therapeutics to explore second-generation mRNA cancer vaccines using Achilles' AI-powered, tumor-targeting technology ...
Arcturus Therapeutics ( ARCT ) Reports Q2 Loss, Tops Revenue Estimates
Arcturus Therapeutics (ARCT) delivered earnings and revenue surprises of 65.41% and 137.42%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
BK Virus Infection Market to Witness Surge in Growth During the Study Period ( 2020-2034 ) | DelveInsight
The BK virus infection market is expanding due to increased awareness and advancements in diagnostic technologies. Rising kidney transplant procedures and the subsequent need for effective treatments and management of BK virus in immunocompromised patients are driving market growth.
